Krogan received his Ph.D. in medical genetics at the University of Toronto in 2006 with Jack Greenblatt as his doctoral advisor.

[6] Krogan serves as Director of The HARC Center, an NIH-funded collaborative group that focuses on the structural characterization of HIV-human protein complexes.

In 2020, Krogan led the work to create the SARS-CoV-2 interactome and assembled the QBI Coronavirus Research Group (QCRG) to study SARS-CoV-2 and to find treatments for Covid-19.

[11] The Center focuses on pandemic preparedness as well as the prediction and treatment of emerging infectious diseases.

[14] Rezo Therapeutics is located in the Bay Area and is based on technology from QBI at UCSF.